Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
MicroRNAs01:22

MicroRNAs

3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Abnormal Proliferation02:23

Abnormal Proliferation

5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic Medicine Sweden: Advancing precision medicine at the national level.

Journal of internal medicine·2026
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

The impact of PSMA-PET/CT on clinical decision-making in primary staging of prostate cancer.

EJNMMI research·2026
Same author

Restriction-Weighted Q-Space Trajectory Imaging (ResQ): Toward Mapping Diffusion-Time Effects With Tensor-Valued Diffusion Encoding in Human Prostate Cancer Xenografts.

NMR in biomedicine·2026
Same author

Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer.

Breast cancer research : BCR·2026
Same author

Towards an ecosystem of clinical decision support tools for precision cancer medicine.

NPJ precision oncology·2026

Related Experiment Video

Updated: Jan 15, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.0K

MicroRNA-379 Modulates Prostate-Specific Antigen Expression Through Targeting the Androgen Receptor in Prostate

James R Cassidy1, Margareta Persson2, Gjendine Voss1

  • 1Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, 22381 Lund, Sweden.

Cancers
|October 16, 2025
PubMed
Summary
This summary is machine-generated.

MicroRNA-379 (miR-379) suppresses prostate cancer (PCa) metastasis by indirectly reducing prostate-specific antigen (PSA) secretion. It achieves this by downregulating the androgen receptor (AR), a key regulator of PSA. This finding offers new insights into PCa progression.

Keywords:
metastasesmicroRNAoncogenic and tumor-suppressive miRNAsprostate cancer

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

Related Experiment Videos

Last Updated: Jan 15, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

25.0K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNA-379 (miR-379) exhibits tumor-suppressive functions in various cancers.
  • Previous research indicated miR-379 overexpression inhibits prostate cancer (PCa) metastasis in vitro and in vivo.
  • The precise mechanisms underlying miR-379's role in PCa metastasis require further elucidation.

Purpose of the Study:

  • To investigate the molecular mechanisms by which miR-379 influences prostate cancer metastasis.
  • To identify secreted proteins regulated by miR-379 in a bone microenvironment model relevant to PCa.
  • To elucidate the regulatory relationship between miR-379, androgen receptor (AR), and prostate-specific antigen (PSA) in PCa.

Main Methods:

  • Utilized a cytokine array to identify secreted proteins affected by miR-379 dysregulation in a bone microenvironment model.
  • Performed functional studies, including reporter assays, to analyze transcriptional regulation.
  • Assessed clinical samples for correlations between miR-379 expression, AR levels, and serum PSA.

Main Results:

  • Prostate-specific antigen (PSA) secretion and intracellular levels were inversely modulated by miR-379 levels.
  • miR-379 was found to indirectly regulate PSA transcription by downregulating androgen receptor (AR) expression via targeting the AR 3'-UTR.
  • Clinical data showed an inverse correlation between prostatic miR-379 expression and serum PSA, and reduced miR-379 correlated with increased AR.
  • miR-379 does not directly regulate PSA expression.

Conclusions:

  • miR-379 negatively regulates PSA secretion indirectly through the suppression of AR.
  • The interaction between miR-379, AR, and PSA is implicated in the bone metastatic progression of prostate cancer.
  • These findings highlight a novel regulatory pathway potentially contributing to PCa pathogenesis and metastasis.